Cooper Companies Likely to Beat Q3 Earnings Estimate on Lens Demand

Cooper Companies (COO) is projected to exceed its fiscal third-quarter earnings estimates, with Zacks Consensus anticipating revenues of $982 million (+5.4% YoY) and EPS of $0.92 (+8.2% YoY), driven by robust global demand for its CooperVision (CVI) contact lenses, particularly MyDay, Clarity, and Biofinity brands. While the CooperSurgical (CSI) segment benefits from minimally invasive surgical devices, its fertility business faces headwinds from declining cycles in Asia-Pacific and tighter clinic cash management, partially offsetting overall growth. The quantitative model indicates a high probability of an earnings beat, reinforcing the strength of COO's core vision product portfolio.

Analysis

Cooper Companies (COO) is positioned for a strong fiscal third-quarter report, with consensus estimates pointing to a 5.4% year-over-year revenue increase to $982 million and an 8.2% rise in earnings per share to $0.92. The primary growth engine is the CooperVision (CVI) segment, which is experiencing robust global demand for its key contact lens brands, including MyDay, Clarity, and Biofinity. This strength is underpinned by new product launches, expanded market penetration, and overall market growth, with model estimates projecting a 6.5% organic sales increase and a significant 11.7% rise in segmental operating income. In stark contrast, the CooperSurgical (CSI) segment faces significant headwinds. While sales from minimally invasive devices and the recently acquired OVP Surgical are growing, this is being offset by persistent weakness in the fertility business, particularly due to declining cycles in the Asia-Pacific market and cautious capital spending by clinics. This pressure, along with an expected Q3 decline in PARAGARD sales, is forecast to cause a substantial 14.4% drop in CSI's operating income. Despite this segmental divergence, the company's consistent history of earnings surprises and a quantitative model predicting a beat suggest the strength in the larger CVI segment is likely to drive overall positive results.

Key Decisions for Investors

• Investors should monitor the upcoming earnings release for confirmation that the CooperVision segment's strength, with its projected 11.7% operating income growth, can successfully outweigh the material weakness in the CooperSurgical division.
• Pay close attention to management's commentary on the fertility business and PARAGARD sales, as any worsening in these areas could signal future margin pressure and temper the full-year outlook.
• Given the positive Earnings ESP and a history of beats, a short-term bullish stance may be warranted, but long-term positions should be evaluated based on the sustainability of CVI's growth and any signs of a turnaround in the challenged CSI segment.